From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Combination trials | Mechanism of action | Phase | ClinicalTrial.gov ID |
---|---|---|---|
Chidamide + CHOP | Anthracycline-containing regimens | I | NCT02809573 |
Chidamide + Cyclophosphamide + Thalidomide | HDAC inhibitor + Immunomodulatory drugs | II | NCT02879526 |
Romidepsin + CHOEP | Anthracycline-containing regimens | I/II | NCT02223208 |
Romidepsin + CHOP | Anthracycline-containing regimens | III | NCT01796002 |
Romidepsin + ICE | Anthracycline-containing regimens | I | NCT01590732 |
Romidepsin + Lenalidomide | HDAC inhibitor + Immunomodulatory drug | II I/II | NCT02232516 NCT01742793 |
Belinostat + Carfilzomib | HDAC inhibitor + proteasome inhibitor | I | NCT02142530 |
Pralatrexate + Romidepsin | HDAC inhibitor + antifolate | I/II | NCT01947140 |
Romidepsin + 5-Azacitadine | hypomethylation agent + HDAC inhibitor | I/II | NCT01998035 |